(Sharecast News) - Diaceutics announced a five-year, multi-product subscription contract with an unnamed "top 30" global pharma company on Thursday, to deliver customised data insights via its 'DXRX' platform.
The AIM-traded firm said the total contract value would be more than $1m, spread across five years and subject to certain milestones, which would "significantly expand" its existing relationship with the company and set it up for future opportunities with the client.
It said the contract would see Diaceutics deliver a core set of real-world data and insights on lab test results, identifying physicians treating patients in target cohorts.
The demand for biomarker test results and interpretation customised to the client's needs in oncology was a "key" value proposition for DXRX Signal, one of the primary products being taken.
"This multi-product, multi-year auto renew contract speaks to how our DXRX platform spans the full diagnostic commercialisation pathway - in this instance providing our client with the insights they need to better engage with prescribers to choose their therapy," said co-founder Ryan Keeling.
"We are encouraged by the pace of deal flow for our newly launched data feeds, which are proving valuable entry points for both new and existing customers onto the DXRX platform."
At 0820 BST, shares in Diaceutics were up 1.43% at 122.22p.
Diaceutics (DXRX)